Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia

Brain

Volumn 131, Issue 6, 2008, Pages 1574-1587

  Lee, Joohyung ^a   Zhu, Wen Mei ^a   Stanic, Davor ^a   Finkelstein, David I ^b   Horne, Marjorie H ^c   Henderson, Jasmine ^d   Lawrence, Andrew J ^a   O'Connor, Louise ^a   Tomas, Doris ^a   Drago, John ^a   Horne, Malcolm K ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^d University of Sydney   (Australia)

Author keywords

Dopamine uptake transporter; Levodopa; Parkinson's disease; Striatum; Voltammetry

Indexed keywords

DOPAMINE; LEVODOPA; OXIDOPAMINE; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; DYSKINESIA; ELECTROCHEMICAL ANALYSIS; IMMUNOREACTIVITY; MALE; MARMOSET; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CALLITHRIX; CORPUS STRIATUM; DOPAMINE; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MODELS, ANIMAL; NEOSTRIATUM; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 44949236082     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn085     Document Type: Article

References (59)

1. Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, Walters J, et al. Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 1997; 17: 6761-8.
2. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-88.
3. Bowyer JF, Weiner N. Modulation of the Ca++-evoked release of [3H]dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists. J Pharmacol Exp Ther 1987; 241: 27-33.
4. Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999; 53: 1212-8.
5. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007; 27: 8011-22.
6. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819-33.
7. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006; 96: 1718-27.
8. Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007; 30: 236-43.
9. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10: 2694-706.
10. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381-92.
11. Cenci MA, Tranberg A, Andersson M, Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999; 94: 515-27.
12. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9.
13. Dan Y, Poo MM. Spike timing-dependent plasticity: from synapse to perception. Physiol Rev 2006; 86: 1033-48.
14. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127: 888-99.
15. Finkelstein DI, Stanic D, Parish CL, Drago J, Horne MK. Stereological procedures for determination of neuronal arbour size. In: Gerfen C, Wray S, editors. Current protocols in neuroscience. New York: Wiley; 2004 p. 1.13.1-1.13.16.
16. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000; 97: 99-112.
17. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984a; 4: 2877-90.
18. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 1984b; 4: 2866-76.
19. Hely MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Rail D, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-10.
20. Henderson JM, Annett LE, Torres EM, Dunnett SB. Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus). Eur J Neurosci 1998; 10: 689-98.
21. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 1997; 388: 211-27.
22. Ikemoto K, Kitahama K, Jouvet A, Arai R, Nishimura A, Nishi K, et al. Demonstration of L-dopa decarboxylating neurons specific to human striatum. Neurosci Lett 1997; 232: 111-4.
23. Lawrence AJ, Parish CL, Chen F, Lodge DJ, Krstew EV, Card K, et al. Chronic corticotropin-releasing factor type 1 receptor antagonism with antalarmin regulates the dopaminergic system of Fawn-Hooded rats. J Neurochem 2005; 94: 1523-34.
24. Letzkus JJ, Kampa BM, Stuart GJ. Learning rules for spike timing-dependent plasticity depend on dendritic synapse location. J Neurosci 2006; 26: 10420-9.
25. Lindgren N, Xu ZQ, Herrera-Marschitz M, Haycock J, Hokfelt T, Fisone G. Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 2001; 13: 773-80.
26. Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res 2003; 969: 135-46.
27. McColl CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002; 17: 1227-34.
28. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 2006; 22: 586-98.
29. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980; 8: 558-63.
30. Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, Totterdell S. Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 1999; 11: 3585-96.
31. Metman LV, van den Munckhof P, Klaassen AA, Blanchet P, Mouradian MM, Chase TN. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997; 49: 711-3.
32. Mirenowicz J, Schultz W. Importance of unpredictability for reward responses in primate dopamine neurons. J Neurophysiol 1994; 72: 1024-7.
33. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988; 24: 372-8.
34. Nakamura K, Ahmed M, Barr E, Leiden JM, Kang UJ. The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant 2000; 9: 567-76.
35. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001; 8: 101-8.
36. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002; 51: 686-93.
37. Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995; 45: 1613-6.
38. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 1992; 49: 1123-30.
39. Onali P, Olianas MC, Bunse B. Evidence that adenosine A2 and dopamine autoreceptors antagonistically regulate tyrosine hydroxylase activity in rat striatal synaptosomes. Brain Res 1988; 456: 302-9.
40. Parish CL, Finkelstein DI, Drago J, Borrelli E, Horne MK. The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci 2001; 21: 5147-57.
41. Parish CL, Stanic D, Drago J, Borrelli E, Finkelstein DI, Horne MK. Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur J Neurosci 2002; 16: 787-94.
42. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612-7.
43. Paxinos G, Watson C. The rat brain in stereotaxic co-ordinates. Sydney: Academic Press; 1998. p. C10-33; C37-43.
44. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995; 10: 731-40.
45. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-6.
46. Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, et al. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 2002; 125: 2635-45.
47. Pickel VM, Johnson E, Carson M, Chan J. Ultrastructure of spared dopamine terminals in caudate-putamen nuclei of adult rats neonatally treated with intranigral 6-hydroxydopamine. Brain Res Dev Brain Res 1992; 70: 75-86.
48. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36: 1528-30.
49. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000a; 356: 44-5.
50. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000b; 356: 44-5.
51. Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov Disord 1999; 14: 605-11.
52. Reynolds JN, Hyland BI, Wickens JR. A cellular mechanism of reward-related learning. Nature 2001; 413: 67-70.
53. Robinson MB. Regulated trafficking of neurotransmitter transporters: common notes but different melodies. J Neurochem 2002; 80: 1-11.
54. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007; 62: 468-74.
55. Stanic D, Finkelstein DI, Bourke DW, Drago J, Horne MK. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 2003a; 18: 1175-88.
56. Stanic D, Parish CL, Zhu WM, Krstew EV, Lawrence AJ, Drago J, et al. Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J Neurochem 2003b; 86: 329-43.
57. Ungerstedt U, Herrera-Marschitz M, Stahle L, Zetterstrom T. Models for studying the synaptic mechanisms: correlative measurements of transmitter release and drug altered behaviour. In: Spiegelstein MY, Levy A, editors. Behavioural models and the analysis of drug action. Amsterdam: Elsevier; 1982. p. 57-70.
58. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. In: Spielgestein MY, Levy A, editors. Anat Rec 1991; 231: 482-97.
59. Winkler C, Kirik D, Bjorklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002; 10: 165-86.